UTHR today
$591.17-$2.14 (-0.36%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourDescending Triangle
1 hourBearish
15 minBearish
5 minConsolidating
Daily trend turns down below $523.95
Key levels
Resistance$614.23
Support$585.79
Support$556.63
Latest news & SEC filings
SEC FilingUnited Therapeutics Corp filed an insider trading report (Form 4)
All UTHR news →About United Therapeutics
United Therapeutics is a biopharmaceutical company that develops and sells therapies for pulmonary arterial hypertension and other rare diseases. Its commercial products include Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, and Adcirca for pulmonary hypertension, plus Unituxin for high-risk neuroblastoma. It sells mainly through drug wholesalers in the United States, with additional sales across Europe, Japan, Canada, and parts of Asia, the Middle East, and Latin America. The company also develops organ manufacturing technologies to expand the supply of transplantable organs.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
UNITED THERAPEUTICS Corp (UTHR)
What Is the Price Target for UTHR?
SEPT Low Target
$321.00
SEPT Mid Target
$660.00
SEPT High Target
$738.00
Analyst Consensus
$660.00
Is UTHR a Buy or Sell Right Now?
Thesis
- •Revenue growing 10.6% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for UTHR.
Start Free Trial →Is UTHR Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$577.21
80
Moat Score
WIDE
8/9
Piotroski Score
24.9
Altman Z-Score
What Is Smart Money Doing with UTHR?
Insider Signal
SELLING
0 buys / 18 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | director officer | Buy | 9,500 | $1.1M | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 25 | $15K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 215 | $126K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 320 | $188K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 271 | $159K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 292 | $172K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 301 | $178K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 736 | $435K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 1,172 | $695K | Nov 11, 2026 |
| ROTHBLATT MARTINE A | director officer | Sale | 961 | $570K | Nov 11, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →UTHR Growth Story
Revenue YoY
10.6%
3yr Revenue CAGR
18.0%
EPS Growth YoY
13.07%
FCF Growth YoY
-3.7%
Revenue Trend
STRONG
Dark Pool Trades for UTHR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for UTHR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:44:23 | $591.17 | 16,655 | $$9.8M | BUY |
| 20:31:36 | $597.42 | 1,000 | $$597K | MIDPOINT |
| 20:25:10 | $596.66 | 1,720 | $$1.0M | MIDPOINT |
| 20:08:49 | $597.39 | 3,713 | $$2.2M | MIDPOINT |
| 20:08:49 | $597.39 | 2,780 | $$1.7M | MIDPOINT |
5 dark pool trades shown · $$15.3M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for UNITED THERAPEUTICS Corp (UTHR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →UTHR — frequently asked questions
What is UTHR stock price today?
UNITED THERAPEUTICS Corp (UTHR) is at $591.17, down 0.36% (-$2.14) at the Nov 13, 2026 close.
Why is UTHR stock moving today?
Latest UTHR news — Nov 10, 2026: United Therapeutics Corp filed an insider trading report (Form 4)
What is the UTHR price target?
The average analyst price target for UTHR is $660.00, ranging from $321 to $738, based on 11 analysts. Latest: JP Morgan maintains on Oct 28, 2026.
What do analysts rate UTHR?
Analyst ratings for UTHR: 2 Buy, 16 Hold, 0 Sell — consensus Hold.
Did UTHR beat earnings?
UTHR last reported on Aug 5, 2026: EPS $7.27 vs $6.86 expected — a beat of 6.0%.
What is UTHR's P/E ratio?
UTHR trades at a P/E of 21.5 vs a Healthcare average of 17.7.
Does UTHR pay a dividend?
UTHR does not currently pay a dividend.
What are UTHR support and resistance levels?
Support: $585.79, $556.63, $523.95. Resistance: $614.23.
What are insiders doing with UTHR?
Insider activity: SELLING, 0 buys and 18 sells in the last 90 days.
What is the latest news on UTHR?
Nov 10, 2026: United Therapeutics Corp filed an insider trading report (Form 4)